title: [Factors involved in the non-compliance of the pharmacologic treatment of dyslipidemia].
abstract: OBJECTIVE
  To find how much non-compliance with lipid-lowering drug treatment there is, its causes and to describe the profile of non-compliant patients.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Primary Care Centres in the province of Alicante.
  
  
  METHODS
  107 patients under drugs treatment for lipaemic disorders and belonging to live General Medical practices.
  
  
  RESULTS
  To evaluate compliance, the method of a surprise count of pills in the patient's home was used. Compliant patients were defined as those with between 80 and 110% compliance. 46.7% were non-compliant (C.I. 37.3-56.2), with 42% under-compliant and 4.7% over. Forgetfulness and unawareness accounted for 68% of the reasons for non-compliance. Associated factors were: moderate to high cardiovascular risk (p = 0.03), stating that the drug treatment was followed badly (p = 0.01), less than a year in regular treatment (p = 0.006), monitoring lipaemia poorly (p = 0.003).
  
  
  CONCLUSIONS
  Non-compliance with pharmacological treatment in patients with lipaemia is high. Its causes are known, as are several factors associated to non-compliance which could be used to identify the non-complier.
authors.affiliation: Departamento de Medicina, Universidad de Alicante.
authors.forename: F
authors.initials: F
authors.lastname: Piñeiro
authors.forename: V
authors.initials: V
authors.lastname: Gil
authors.forename: R
authors.initials: R
authors.lastname: Pastor
authors.forename: M
authors.initials: M
authors.lastname: Donis
authors.forename: M T
authors.initials: MT
authors.lastname: Torres
authors.forename: J
authors.initials: J
authors.lastname: Merino
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016312:Treatment Refusal / Q000706:statistics & numerical data*
vernacular_title: Factores implicados en el incumplimiento del tratamiento farmacológico en las dislipemias.